With full enrollment for the PII trial of NurOwn targeted for late this year and top-line data not available until mid-2016 I see no catalyst for this stock to move anytime soon. Am I missing something?
It's important to note that when Zacks or anyone else provides a target price it rarely has a target date. That's a post-Phase III target and Phase III will hopefully begin in 2017.
News 
Market Data 
Discover 
